Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tarak Choksi

Geriatric Medicine Trinity, FL Medical Doctor

NPI 1154421766 CMS profile 143648

1838 Health Care Dr Unit 2, Trinity, FL 34655

Open in the dashboard

General payments

$4,842

280 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tarak Choksi of Trinity, FL is reported in the CMS Open Payments database as having received $4,842 across 280 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26 1
2023 General $662 31
2022 General $1,167 63
2021 General $1,288 74
2020 General $1,047 62
2019 General $652 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tarak Choksi
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Tarak Choksi were reported at $26. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Tarak Choksi Geriatric Medicine median Middle half National median
2019 $652 $122 $40–$435 $163
2020 $1,047 $98 $25–$349 $114
2021 $1,288 $125 $34–$441 $132
2022 $1,167 $124 $36–$408 $149
2023 $662 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $26 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,188 70 payments
  2. AstraZeneca Pharmaceuticals LP $934 59 payments
  3. Janssen Pharmaceuticals, Inc $454 32 payments
  4. Pfizer Inc. $384 22 payments
  5. Novo Nordisk Inc $377 18 payments
  6. Lilly USA, LLC $354 22 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $270 12 payments
  8. Novartis Pharmaceuticals Corporation $232 14 payments
  9. Amarin Pharma Inc. $186 9 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $182 7 payments
  11. Other $281 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,828 277 payments
  2. Education $14 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,035 59 payments
  2. FARXIGA $618 39 payments
  3. XARELTO $449 31 payments
  4. ELIQUIS $366 21 payments
  5. Ozempic $353 17 payments
  6. RYBELSUS $320 15 payments
  7. ANORO ELLIPTA $242 17 payments
  8. ENTRESTO $232 14 payments
  9. JARDIANCE $199 8 payments
  10. PAXLOVID $186 11 payments
  11. Other $2,232 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 121 drugs

Part D claims

7,402

Median for Internal Medicine: 777

Drug cost

$404,684

Median for Internal Medicine: $73,373

Branded share of claims

14.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 87 $106,221
Jardiance Empagliflozin Brand 40 $53,003
Farxiga Dapagliflozin Propanediol Brand 24 $29,514
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 28 $28,297
Xarelto Rivaroxaban Brand 25 $22,005
Januvia Sitagliptin Phosphate Brand 17 $21,497
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $16,003
Ondansetron Hcl Generic 16 $7,715
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 16 $7,056
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 42 $5,740

The 10 drugs with the highest cost, of 121 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$3,757

Medicare's payments for the services billed

Medicare patients

29

Average age 76

Services billed

67

14 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 45%
Depression 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

280 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record